US FDA accepts Mylan ’s BLA for proposed trastuzumab product

Biocon and Mylan have announced acceptance of the latter ’s biologics licence application (BLA) by the US Food and Drug Administration (FDA) for MYL-1401O, a proposed biosimilar trastuzumab.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news